Patient information leaflets (PILs) are changing...
PILs (Patient Information Leaflets) are improving in quality as a result of new legal obligations on manufacturers to test the documents on potential patients. Testing makes sure that the presentation of the information enables patients to find and understand key messages for safe use of the medicine within the PIL and thereby enable them to use the medicine safely and effectively. To promote this new initiative and share best practice, we are publishing a series of examples below to illustrate improvements and to aid learning. All leaflets associated with this scheme are published with the agreement of the marketing authorisation holder responsible for the medicine to which they relate.
The leaflets in this scheme have been supported by a user test carried out in compliance with article 59(3) of Council Directive 2001/83/EC. However, quality of the information can be assessed in other ways. The Commission on Human Medicines Expert Advisory Group on Patient Information has developed a quality scoring system to help identify by means of a numerical score good quality patient information. Leaflet included in this initiative have scored significantly higher in the new layout and design than previously. Marketing authorisation holders may find it helpful to use this scoring system to help develop better quality patient information leaflets:
›
Quality criteria for patient information leaflets
(18Kb)
A selection of patient information leaflets demonstrating best practice:
Enquiries should be directed to patient.information@mhra.gsi.gov.uk